<PAGE> 1



              SECURITIES AND EXCHANGE COMMISSION

                    Washington, D.C.  20549

                           FORM 10-Q



(Mark One)

[ X ]     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
          THE SECURITIES EXCHANGE ACT OF 1934

          For the quarterly period ended June 30, 1999

                              OR

[    ]    TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
          THE SECURITIES EXCHANGE ACT OF 1934

          For the transition period from_______________to_______________

          Commission file number 0-12992

                       SYNTHETECH, INC.
    (Exact name of registrant as specified in its charter)

              Oregon                         84-0845771
   (State or Other Jurisdiction           (I.R.S. Employer
    of Incorporation or Organization)      Identification No.)

      1290 Industrial Way, Albany, Oregon        97321
   (Address of Principal Executive Offices)    (Zip Code)

                         (541) 967-6575
     (Registrant's Telephone Number, Including Area Code)

      Indicate by check mark whether the registrant:  (1)  has
filed  all reports required to be filed by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12
months  (or  for  such shorter period that the registrant  was
required  to file such reports), and (2) has been  subject  to
such filing requirements for the past 90 days.

Yes  X    No_____

      The  number of shares of the registrant's common  stock,
$.001  par  value,  outstanding  as  of  August  9,  1999  was
14,254,630.


<PAGE> 2

                    PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements


                          SYNTHETECH, INC.

                           BALANCE SHEETS
                      -------------------------
<TABLE>
<CAPTION>
<S>                                 <C>           <C>
                                      (unaudited)
                                        June 30,       March 31,
                                          1999           1999
---------------------------            ---------       ---------
ASSETS
------

CURRENT ASSETS:
  Cash and cash equivalents           $  7,736,000  $  7,470,000
  Accounts receivable, less
   allowance for doubtful accounts
   of $15,000 for 1999 and 1998          2,470,000     3,414,000
  Inventories                            3,376,000     3,359,000
  Prepaid expenses                         287,000       284,000
  Deferred income taxes                    133,000       133,000
  Other current assets                      17,000         5,000
                                        ----------    ----------
   TOTAL CURRENT ASSETS                 14,019,000    14,665,000


PROPERTY, PLANT AND EQUIPMENT,
 at cost, net                           12,010,000    11,561,000

OTHER ASSETS                                 4,000         4,000
                                      ------------  ------------
   TOTAL ASSETS                       $ 26,033,000  $ 26,230,000
                                      ============  ============

                 See Notes To Financial Statements.
</TABLE>
<PAGE> 3

                          SYNTHETECH, INC.

                           BALANCE SHEETS
                      -------------------------
                            (continued)
<TABLE>
<CAPTION>
<S>                                       <C>                <C>
                                           (unaudited)
                                             June 30,          March 31,
                                               1999               1999
------------------------------------         ----------         --------
LIABILITIES AND SHAREHOLDERS' EQUITY
------------------------------------

CURRENT LIABILITIES:
  Current portion of note payable         $     15,000      $     15,000
  Accounts payable                             440,000         1,543,000
  Accrued compensation                         147,000           375,000
  Deferred revenue                              44,000            44,000
  Accrued income taxes                         681,000           561,000
  Other accrued liabilities                     10,000            17,000
                                             ---------         ---------
   TOTAL CURRENT LIABILITIES                 1,337,000         2,555,000

DEFERRED INCOME TAXES                          496,000           496,000

NOTE PAYABLE, net of current portion           148,000           152,000

SHAREHOLDERS' EQUITY:
 Common stock, $.001 par value;
  authorized 100,000,000 shares;
  issued and outstanding, 14,255,000
  and 14,252,000 shares                         14,000            14,000
 Paid-in capital                             8,750,000         8,740,000
 Deferred  compensation                        (66,000)          (76,000)
 Retained earnings                          15,354,000        14,349,000
                                            ----------        ----------
  TOTAL SHAREHOLDERS' EQUITY                24,052,000        23,027,000
                                          ------------      ------------
  TOTAL LIABILITIES AND
   SHAREHOLDERS' EQUITY                   $ 26,033,000      $ 26,230,000
                                          ============      ============

                  See Notes To Financial Statements.
</TABLE>
<PAGE> 4



                           SYNTHETECH, INC.

                         STATEMENTS OF INCOME
                    --------------------------------
                             (unaudited)
<TABLE>
<CAPTION>
<S>                                          <C>               <C>
For The Three Month Period Ended June 30           1999             1998
----------------------------------------           -----            -----

REVENUES                                       $ 4,636,000      $ 4,128,000
COST OF SALES                                    2,629,000        2,535,000
                                                 ---------        ---------
GROSS PROFIT                                     2,007,000        1,593,000


RESEARCH AND DEVELOPMENT                           127,000           81,000
SELLING, GENERAL AND ADMINISTRATIVE                343,000          355,000
                                                   -------          -------
OPERATING EXPENSE                                  470,000          436,000
                                                 ---------        ---------
OPERATING INCOME                                 1,537,000        1,157,000
OTHER INCOME, net                                   87,000           63,000
INTEREST EXPENSE                                    (3,000)          (4,000)
                                                 ---------        ---------
INCOME BEFORE INCOME TAXES                       1,621,000        1,216,000

PROVISION FOR INCOME TAXES                         616,000          462,000
                                               -----------      -----------
NET INCOME                                     $ 1,005,000      $   754,000
                                               ===========      ===========

BASIC EARNINGS PER SHARE                            $0.07             $0.05
                                                    =====             =====

DILUTED EARNINGS PER SHARE                          $0.07             $0.05
                                                    =====             =====

                        See Notes To Financial Statements.
</TABLE>
<PAGE> 5

                          SYNTHETECH, INC.

                      STATEMENTS OF CASH FLOWS
                  ----------------------------------
                            (unaudited)
<TABLE>
<CAPTION>
<S>                                             <C>                <C>
For The Three Month Period Ended June 30             1999             1998
----------------------------------------           --------         --------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income                                        $ 1,005,000      $  754,000
Adjustments to reconcile net income to
 net cash provided by operating activities:
   Depreciation, amortization and other               386,000         219,000
   Amortization of deferred compensaton                13,000          29,000

   (Increase) decrease in assets:
     Accounts receivable, net                         944,000        (296,000)
     Inventories                                      (17,000)       (688,000)
     Prepaid expenses                                  (3,000)         80,000
     Other assets                                     (12,000)         19,000

   Increase (decrease) in liabilities:
     Accounts payable and accrued liabilities      (1,218,000)        734,000
     Deferred revenue                                       -         134,000
                                                     ---------        -------
      Net cash provided by operating activities      1,098,000        985,000
                                                     ---------        -------
CASH FLOWS FROM INVESTING ACTIVITIES:
   Property, plant and equipment purchases            (835,000)      (419,000)
                                                      --------       --------
      Net cash used in investing activities           (835,000)      (419,000)
                                                      --------       --------
CASH FLOWS FROM FINANCING ACTIVITIES:
   Principal payments under long-term
    debt obligations                                    (4,000)        (3,000)
   Proceeds from stock option exercises
    and disqualifying dispositions                       7,000          1,000
                                                         -----         ------
      Net cash provided by (used in)
       financing activities                              3,000         (2,000)
                                                       -------        -------
NET INCREASE IN CASH AND CASH EQIVALENTS               266,000        564,000

CASH AND CASH EQUIVALENTS AT BEGINNING
 OF PERIOD                                           7,470,000      4,976,000
                                                   -----------    -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD         $ 7,736,000    $ 5,540,000
                                                   ===========    ===========
NON-CASH INVESTING ACTIVITIES:
   Issuance of stock options at below fair value   $     4,000    $    38,000
   Mature shares exchanged  for the exercise
    of stock options                               $         -    $   231,000

                          See Notes To Financial Statements.
</TABLE>
<PAGE> 6




                 NOTES TO FINANCIAL STATEMENTS


NOTE A.   GENERAL AND BUSINESS


The  summary  financial statements included herein  have  been
prepared, without audit, pursuant to the rules and regulations
of   the   Securities   and  Exchange   Commission.    Certain
information  and  footnote disclosures  normally  included  in
financial  statements  prepared in accordance  with  generally
accepted accounting principles have been condensed or  omitted
pursuant  to  such rules and regulations, although  Synthetech
management believes that the disclosures are adequate to  make
the  information  presented not misleading.  It  is  suggested
that these summary financial statements be read in conjunction
with  the  financial statements and the notes thereto included
in Synthetech's fiscal 1999 Form 10-K.

  Interim  financial  statements  are  by  necessity  somewhat
tentative;  judgments are used to estimate  quarterly  amounts
for  items  that are normally determinable only on  an  annual
basis.  For example, provision for income taxes is an estimate
of  the  annual liability pro-rated over the quarters  of  the
fiscal year based on estimates of annual income.  Further, all
inventory  quantities are verified by physically counting  the
units  on  hand  at  least  once a year.   Normally,  selected
inventories are counted at the end of each quarter.  For those
inventories not counted at the end of the quarter,  quantities
are  determined using measured sales and production  data  for
the period.

  The interim period information included herein reflects  all
adjustments   which   are,  in  the  opinion   of   Synthetech
management, necessary for a fair statement of the  results  of
the  respective  interim periods.  Results of  operations  for
interim  periods are not necessarily indicative of results  to
be expected for an entire year.


NOTE B.   STATEMENTS OF CASH FLOWS

          Supplemental cash flow disclosures for the three
month period ended June 30:
<TABLE>
<CAPTION>
<S>                                <C>       <C>
          Cash Paid
          ---------
                                 1999              1998
                                 ----              ----
            Income Taxes       $ 490,000         $  15,000
            Interest           $   4,000         $   4,000
</TABLE>


<PAGE> 7

           NOTES TO FINANCIAL STATEMENTS (continued)

NOTE C. EARNINGS PER SHARE

Basic  earnings per share (EPS) are computed by  dividing  net
income  by  the  weighted average number of shares  of  common
stock  outstanding  during the period.  Diluted  earnings  per
share  are  computed by dividing net income  by  the  weighted
average  number  of shares of common stock  and  common  stock
equivalents  outstanding during the period,  calculated  using
the  treasury  stock method as defined in SFAS No.  128.   The
following  is a reconciliation of the shares used to calculate
basic earnings per share and diluted earnings per share:

<TABLE>
<CAPTION>
<S>                                        <C>         <C>
    For The Three Months Ended June 30         1999        1998
    ----------------------------------         ----        ----
    Weighted average shares outstanding
     for Basic EPS                          14,252,108  14,159,981

    Dilutive effect of Common stock
     options issuable under treasury
     stock method                               67,494     108,781
                                            ----------  ----------
    Weighted average common and common
     equivalent shares outstanding for
     diluted EPS                            14,319,602  14,268,762
                                            ==========  ==========
</TABLE>
The  following common stock equivalents were excluded from the
earnings per share computation because their effect would have
been anti-dilutive:

<TABLE>
<CAPTION>
<S>                                          <C>       <C>
    For The Three Months Ended June 30         1999       1998
    ----------------------------------         ----       ----
    Common stock options outstanding          523,800    466,800
</TABLE>

NEW ACCOUNTING PRONOUNCEMENT

In   June   1999,  the  FASB  issued  Statement  of  Financial
Accounting  Standards  No.  137,  "Accounting  for  Derivative
Instruments and Hedging Activities" ("SFAS 137").  SFAS 137 is
an  amendment  to Statement of Financial Accounting  Standards
No.  133,  "Accounting for Derivative Instruments and  Hedging
Activities".   SFAS 137 establishes accounting  and  reporting
standards  for  all  derivative  instruments.   SFAS  137   is
effective  for  fiscal years beginning after  June  15,  2000.
Synthetech  does not currently have any derivative instruments
and, accordingly, does not expect the adoption of SFAS 137  to
have  an  impact  on  its  financial position  or  results  of
operations.

<PAGE> 8



Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations


RESULTS OF OPERATIONS

The following table sets forth, for the periods indicated, the
percentage  of revenues represented by each item  included  in
the Statements of Income.

                          Percentage of Revenues
                        -------------------------
<TABLE>
<CAPTION>
<S>                                          <C>         <C>
For The Three Month Period Ended June 30        1999        1998
----------------------------------------       ------      ------

Revenues                                       100.0 %     100.0 %
Cost of sales                                   56.7 %      61.4 %
                                               ------      ------
Gross Profit                                    43.3 %      38.6 %

Research and Development                         2.7 %       2.0 %
Selling, General and Administration              7.4 %       8.6 %
                                               ------      ------
Operating expense                               10.1 %      10.6 %
                                               ------      ------
Operating Income                                33.2 %      28.0 %
Other Income, net                                1.9 %       1.5 %
Interest Expense                                (0.1)%      (0.1)%
                                               ------      ------
Income Before Income Taxes                      35.0 %      29.4 %

Provision For Income Taxes                      13.3 %      11.2 %
                                               ------      ------
Net Income                                      21.7 %      18.2 %
                                               ======      ======
</TABLE>
Revenues
--------
Revenues  increased  by  12% to $4.64  million  in  the  first
quarter of fiscal 2000 from $4.13 million in the first quarter
of fiscal 1999.  International sales, mainly to Mexico and
Europe, were $3.00 million in the first quarter of fiscal 2000
as  compared to $1.26 million for the first quarter of  fiscal
1999, representing a 138% increase.  International sales, like
all  Company  revenues,  are subject to significant  quarterly
fluctuations.

<PAGE> 9

Item  2.   Management's Discussion and Analysis  of  Financial
Condition and Results of Operations (continued)

The  increase in revenues for the first quarter of fiscal 2000
over the same period of fiscal 1999 principally reflected  the
$2.75  million  revenue contribution from a large-scale  order
for a marketed drug compared to its $2.22 million contribution
to  revenues  last  fiscal  year.   With  the  final  $400,000
shipment  of  this large-scale order occurring in July,  1999,
the Company expects that the results for the second quarter of
fiscal  2000 will be lower than the first quarter fiscal  2000
results.   Nevertheless, Synthetech continues to be an  active
supplier  of  a  diverse set of PBBs, including several  novel
PBBs  for  a  handful of projects advancing  through  clinical
trials.  While it is difficult to predict the timing or extent
of  the business opportunities associated with this handful of
projects,  they  have  the potential to  generate  significant
future revenue. (See "Industry Factors" below.)



Gross Profit
------------
Gross profit was $2.01 million or 43% of revenues in the first
quarter of fiscal 2000 as compared to $1.59 million or 39%  of
revenues in the first quarter of fiscal 1999.  The increase in
gross  profit  margin  for the first quarter  of  fiscal  2000
primarily  reflects  manufacturing  and  process  improvements
associated   with  the  large-scale  order.    These   results
demonstrate   the   Company's  ability  to  generate   ongoing
operating efficiencies and lower variable costs over the  life
cycle of a large-scale project.


Operating Expenses
------------------
Research  and development (R&D) expense increased to  $127,000
in  the first quarter of fiscal 2000 from $81,000 in the first
quarter  of  fiscal 1999.  As a percentage  of  revenues,  the
first quarter of fiscal 2000 was nearly 3% compared to 2%  for
the  first quarter of fiscal 1999. The increase in R&D expense
primarily  reflected  increases  in  staffing  and  associated
expenses.  Selling, general and administrative (SG&A)  expense
was  $343,000 in the first quarter of fiscal 2000 compared  to
$355,000 in the first quarter of fiscal 1999, or 7% and 9%  as
a  percentage  of  revenues, respectively.   In  both  periods
operating  expenses were approximately 10% as a percentage  of
revenues.


Operating Income
----------------
Operating  income  increased to $1.54  million  in  the  first
quarter  of  fiscal 2000 compared with $1.16  million  in  the
first  quarter of fiscal 1999.  As a percent of revenues,  the
first  quarter  of  fiscal 2000 was 33%  compared  to  28%  of
revenues for the same period of fiscal 1999.


Other Income
------------
The  net  other  income of $87,000 and $63,000  in  the  first
quarter   of   fiscal  2000  and  fiscal  1999,  respectively,
primarily reflected interest earnings.

<PAGE> 10

Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)

Net Income
----------
For  the first quarter of fiscal 2000 the Company earned $1.62
million before income taxes.  A provision for income taxes  of
$616,000  resulted  in  net  income  of  $1.01  million.   The
Company's effective tax rate was 38% for the first quarter  of
fiscal 2000 and the first quarter of fiscal 1999.


INDUSTRY FACTORS

The  market for PBBs is driven by the market for synthetically
manufactured peptide, peptidomimetic small molecule and  other
drugs  in  which  they are incorporated. The drug  development
process  for these drugs is dictated by the marketplace,  drug
companies and the regulatory environment. The Company  has  no
control over the pace of these drug development efforts, which
drugs  get  selected  for  clinical trials,  which  drugs  are
approved by the FDA and, even if approved, the ultimate market
potential of such drugs.

The three stages of the drug development process include:  R&D
or  discovery  stage, clinical trial stage and  marketed  drug
stage. Synthetech's customers can spend years researching  and
developing  new  drugs,  taking only  a  small  percentage  to
clinical  trials  and  fewer  yet  to  commercial  market.   A
substantial amount of the activity continues to occur  at  the
earlier  stages  of  research  and  development  and  clinical
trials.  The  market  for  peptide  and  peptidomimetic  small
molecule drugs is still very early in development.

Recurring  sales of PBBs for development programs is  sporadic
at  best.  The  high  cancellation rate for  drug  development
programs  results in a significant likelihood that there  will
be  no  subsequent or "follow-on" PBB sales for any particular
drug development program. Accordingly, the level of purchasing
by  the  Company's  customers for  specific  drug  development
programs varies substantially from quarter to quarter and  the
Company  cannot rely on any one customer as a constant  source
of revenue.

The  size  of  the  PBB  orders  for  marketed  drugs  can  be
substantially larger than those for the discovery or  clinical
trial  stages.  Sales  of  PBBs for marketed  drugs  can  also
provide an opportunity for continuing longer-term sales. While
not  subject  to  the  same high cancellation  rate  faced  by
discovery  and clinical trial stage drug development programs,
the demand for the approved drugs, however, remains subject to
many  uncertainties, including, without limitation,  the  drug
price,  the  drug  side  effects and the  existence  of  other
competing  drugs.  These factors, which  are  outside  of  the
control  of  the Company, will affect the level of demand  for
the  drug  itself and, therefore, the demand for  PBBs.  Also,
industry cost pressures can cause pharmaceutical companies  to
explore and, as was the case with one of the fiscal 1999 large-
scale   orders,  ultimately  adopt  alternative  manufacturing
processes  which  do  not include the  Company's  PBBs  as  an
intermediate.  Finally,  with  the  longer-term,  larger-scale
orders,  the Company expects increased competition  to  supply
these PBBs.

Accordingly,  these industry factors create an  inability  for
the  Company to predict future demand beyond its current order
base.  Until the Company develops a stable baseload of demand,
the  Company  is likely to continue to experience  significant
fluctuations in its quarterly results.

<PAGE> 11

Item 2.  Management's Discussion and Analysis of Financial
Condition and Results of Operations (continued)

LIQUIDITY AND CAPITAL RESOURCES

At  June  30, 1999, the Company had working capital of  $12.68
million  compared to $12.11 million at March  31,  1999.   The
Company's  cash and cash equivalents at June 30, 1999  totaled
$7.74  million.   The  Company does not invest  in  derivative
securities.   In  addition,  the  Company  had  a  $1  million
unsecured  bank line of credit of which there  was  no  amount
outstanding at June 30, 1999.

The  decrease in accounts receivable to $2.47 million at  June
30,  1999  from $3.41 million at March 31, 1999 reflected  the
timing  of  shipments  during the quarter.   The  decrease  in
accounts  payable  to  $440,000 at June 30,  1999  from  $1.54
million  at  March  31,  1999  reflected  reduced  expenditure
commitments related to the second-phase of the plant expansion
and  reduced raw material purchases.  The decrease in  accrued
compensation  to  $147,000 at June 30, 1999 from  $375,000  at
March  31, 1999 primarily reflected accrued bonus and  related
compensation paid during the quarter.

The Company had approximately $835,000 of capital expenditures
during  the  first three months of fiscal 2000.  Approximately
$118,000 was spent for equipment and equipment upgrades in the
existing plant and $717,000 was spent for the second-phase  of
the  new  plant  expansion.   The  Company  anticipates  total
capital expenditures for fiscal 2000 for the existing plant to
be  $1.3  million and for the second-phase of  the  new  plant
expansion to be $2.2 million for a total of $3.5 million.  The
Company  expects  to finance these capital  expenditures  from
internal  cash flow and does not anticipate the need  for  any
new debt or equity financing.



YEAR 2000

The  Year  2000 ("Y2K") issue arose as the result of  existing
computer  programs that use only the last two digits to  refer
to  a  year. Any of the Company's computer programs that  have
date-sensitive software may recognize a date using "00" as the
year  1900  rather than the year 2000. If not corrected,  many
computer applications could fail or create erroneous results.

The  Company  has  established a Y2K team lead  by  its  Chief
Financial  Officer. The team has completed its  assessment  of
the  Company's  information  systems  which  support  business
applications.   The  Company  utilizes  packaged   application
strategies  for  these  information  systems  functions.   The
Company believes that these information system components  are
current  with all Y2K updates and changes recommended  by  the
vendors.   These   information  systems   include   enterprise
software,    operating    systems,   networking    components,
application  and  data servers, PC hardware  and  core  office
automation   software.  The  team  has  also   completed   its
assessment   of   the  Company's  research  and   development,
manufacturing processes and facility management  systems.  The
Company  believes  that  these  systems  and  components   are
current, or will be current by the end of September 1999, with
all  Y2K updates and changes recommended by the vendors.   The
Company  is undertaking a Y2K supplier and customer assessment
program. It is in the process of contacting key suppliers  and
customers to determine the level of their Y2K readiness.

<PAGE> 12

Item  2.   Management's Discussion and Analysis  of  Financial
Condition and Results of Operations (continued)

The  Company's information technology expenditures for  fiscal
1999  were $90,000, of which approximately 22% related to  the
Company's  Y2K  program.  These  expenses  were  paid  out  of
revenues   from   operations.    In   connection   with    its
responsibility  to undertake a Y2K program,  the  Company  has
hired  an outside consultant to provide limited advice to  the
Company's Y2K team and Board of Directors on the Company's Y2K
program.  The Company has  hired another outside consultant to
assist  the  Company's  Y2K  team in  developing  and  running
certain  Y2K  on-site testing protocols. The  Company  expects
that  these activities will be completed by the end of  Summer
1999 and has budgeted $20,000 for these consultants.

Like all businesses, the Company will be at risk from external
infrastructure failures that could arise from Y2K failures. It
is  not  clear  that electrical power, telephone and  computer
networks,  for  example, will be fully functional  across  the
nation  in  the  year 2000. Investigation  and  assessment  of
infrastructures, like the nations' power grid, is  beyond  the
scope and resources of the Company. Investors should use their
own awareness of the issues in the nations' infrastructure  to
make   ongoing  infrastructure  risk  assessments  and   their
potential impact to a company's performance.

It  should  also be noted that there have been predictions  of
failures    of    key   components   in   the   transportation
infrastructure due to the Y2Kissue. It is possible that  there
could  be delays in rail, over-the-road and air shipments  due
to  failure  in  transportation control systems. Investigation
and validation of the world's transportation infrastructure is
beyond  the scope and the resources of the Company.  Investors
should  use their own awareness of the issues in the  nations'
infrastructure to make ongoing infrastructure risk assessments
and their potential impact to a company's performance.

The failure to correct a material Y2K problem could result  in
an  interruption in, or a failure of, certain normal  business
activities  or operations. Such failures could materially  and
adversely   affect  the  Company's  results   of   operations,
liquidity   and  financial  condition.  Due  to  the   general
uncertainty inherent in the Y2K issue, resulting in part  from
the  uncertainty of the Y2K readiness of third-party suppliers
and customers, the Company is unable to determine at this time
whether  the consequences of Y2K failures will have a material
impact  on  the Company's results of operations, liquidity  or
financial condition. The Company's efforts to help ensure  Y2K
preparedness   are  expected  to  significantly   reduce   the
Company's  level  of  uncertainty about  the  Y2K  issue.  The
Company  believes that, with completion of the above-mentioned
system  upgrades and testing, the possibility  of  significant
interruptions of normal operations should be reduced.

During  the  Summer of 1999, the Company intends to  determine
whether,  and to what extent, to develop contingency plans  in
regard  to  Y2K issues. The Company expects to have  completed
any  contingency plans that it decides to undertake by the end
of Fall 1999.

               ___________________________________

This Form 10-Q includes  "forward-looking"  information  (as
defined  in  Section  27A  of  the Securities  Act  of  1933
and Section 21E  of  the  Securities Exchange  Act of 1934).
Investors are cautioned   that  forward-looking   statements
involve  risks  and  uncertainties,   and  various   factors
could  cause  actual  results   to   differ materially  from
those  in  the  forward-looking statements.  Forward-looking
statements include, without  limitation,  any statement that
may predict,   forecast,  indicate  or imply future results,
performance     or      achievements,       and         may

<PAGE> 13

Item  2.   Management's Discussion and Analysis  of  Financial
Condition and Results of Operations (continued)

contain   the   words   "believe,"   "anticipate,"   "expect,"
"estimate,"  "project,"  "will  be,"  "will  continue,"  "will
likely result," or words or phrases of similar meanings.   The
risks  and uncertainties include, but are not limited to,  the
following:   the  uncertain  market  for  products,   customer
concentration,   potential  quarterly  revenue   fluctuations,
industry  cost  factors,  competition, government  regulation,
product liability risks, technological change, increased costs
associated    with   the   Company's   facility    expansions,
international  business risks, and Y2K risks.   Investors  are
directed  to  the  Company's filings with the  Securities  and
Exchange Commission, including the Company's Form 10-K for the
fiscal year ended March 31, 1999, which are available from the
Company without charge, for a further description of the risks
and  uncertainties related to forward-looking statements  made
by  the  Company as well as to other aspects of the  Company's
business.





                  PART II - OTHER INFORMATION

Item 6.  Exhibits and Reports on Form 8-K

(a)  Exhibits

       3(i)*   Articles of Incorporation of Synthetech, Inc., as amended.

       3(ii)   Bylaws of Synthetech, Inc., as amended.

      27       Financial Data Schedule

__________________

      *Incorporated by reference herein from the Company's
      Form 10-KSB for the year ended March 31, 1997.


(b)  Reports

     No reports on Form 8-K were filed during the quarter.

<PAGE> 14

                          SIGNATURES



Pursuant to the requirements of the Securities Exchange Act of
1934,  the registrant has duly caused this report to be signed
on its behalf by the undersigned thereunto duly authorized.






                                        SYNTHETECH, INC.
                                         (Registrant)



Date:  August 10, 1999                  /s/M. Sreenivasan
                                        M. Sreenivasan
                                        President & C.E.O.



Date:  August 10, 1999                  /s/  Charles B. Williams
                                        Charles B. Williams
                                        Vice President, Finance
                                        and  Administration, C.F.O.,
                                        Chief Accounting Officer

<PAGE> 15

                         INDEX TO EXHIBITS



                                                        Sequential Page No.


  3(ii)  Bylaws of Synthetech, Inc., as amended.

 27      Financial Data Schedule for Three Months Ended
         June 30, 1999